Treatment 8 min
Endometrial cancer: treatment after surgery and the role of molecular testing
Endometrial (uterine) cancer: risk groups after surgery, four molecular subtypes, when brachytherapy, radiotherapy and chemotherapy are needed, and immunotherapy for advanced disease.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026
Endometrial cancer (cancer of the body of the uterus) is most often found early, because it shows itself with bleeding, especially after menopause. The basis of treatment is surgery, and whether chemotherapy or radiotherapy is needed afterwards is today decided not only by stage but also by the molecular subtype of the tumour. This has changed the approach: some patients can be treated more gently, and some more intensively.
In this article I explain how risk is assessed after surgery, what the four molecular subtypes are, when observation is enough, when brachytherapy, external radiotherapy or chemotherapy is needed, and what is offered for advanced and recurrent disease.
What the pathology shows and which tests are needed
After surgery the pathologist describes:
- histological type: endometrioid adenocarcinoma (the most common), serous, clear cell, carcinosarcoma and others;
- grade: low or high grade (what grade means);
- depth of invasion into the myometrium and involvement of the cervix, ovaries and lymphatic vessels (lymphovascular invasion);
- stage by FIGO and TNM (TNM in plain words).
In addition, molecular testing is done: immunohistochemistry for the mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), p53 and, if needed, sequencing of the POLE gene. It is worth asking for this if your report does not mention it. More on reading the report: how to read a pathology report.
The four molecular subtypes
| Subtype | What it is | What it usually means for treatment |
|---|---|---|
| POLE-mutated | A mutation in the POLE gene, very many mutations in the tumour | Prognosis is usually very favourable; in early stage additional treatment can often be avoided |
| dMMR / MSI-H | The DNA repair system is impaired (MSI and dMMR) | The tumour responds well to immunotherapy; in early stage the approach depends on risk |
| NSMP | No specific profile, more often hormone-driven | Sensitivity to hormonal therapy often remains; treatment is set by stage and grade |
| p53abn | Abnormal p53, often serous type | More aggressive course; chemotherapy is more often needed even in early stage |
Repair deficiency is also a reason to think about hereditary Lynch syndrome: a genetic consultation and testing of relatives are then discussed.
Surgery
The standard in endometrial cancer is removal of the uterus with both tubes and ovaries (hysterectomy with bilateral salpingo-oophorectomy). It is most often done laparoscopically or with a robot, and by open surgery in high-risk or special situations.
The second part of the operation is assessing the lymph nodes. Today a sentinel lymph node biopsy (the node that receives lymph from the tumour first) is used more often than removal of all pelvic and para-aortic nodes. It lowers the risk of lymphoedema and still gives staging information. For serous and clear cell cancer and carcinosarcoma the operation is usually wider and includes removal of the omentum.
Risk groups after surgery
To decide whether treatment is needed, the tumour is assigned to a risk group. As a guide:
| Risk group | Examples | What is usually recommended |
|---|---|---|
| Low | Early stage, low grade, superficial invasion, POLE or NSMP | Observation |
| Intermediate | Early stage but deeper invasion or other factors | Observation or vaginal brachytherapy |
| High-intermediate | Lymphovascular invasion, high grade | Brachytherapy or external radiotherapy, sometimes chemotherapy |
| High | Advanced stage, serous type, p53abn | Chemotherapy plus radiotherapy, chosen individually |
The exact choice is made by a tumour board taking into account molecular subtype, age, general condition and your wishes. The logic is described in neoadjuvant and adjuvant therapy.
What each treatment after surgery offers
- Brachytherapy (radiation from inside the vagina, usually a few sessions) lowers the risk of recurrence at the vaginal vault and is easier to tolerate than external radiotherapy.
- External beam radiotherapy covers the pelvis. It lasts several weeks; diarrhoea, bladder and bowel irritation and fatigue are possible.
- Chemotherapy is usually carboplatin with paclitaxel, about six cycles. It is more often given in stage III–IV, serous and clear cell cancer and in p53abn. More: platinum drugs and paclitaxel.
- Combined chemo- and radiotherapy is used in high risk. Data from the PORTEC-3 trial showed that in p53abn adding chemotherapy to radiotherapy brings a noticeable benefit.
Advanced and recurrent endometrial cancer
If the disease has spread or returned, the approach changes.
First line in advanced or recurrent disease: chemotherapy with carboplatin and paclitaxel together with immunotherapy (dostarlimab or pembrolizumab). In the RUBY and NRG-GY018 trials this combination improved results, especially in patients with dMMR/MSI-H tumours. More: immunotherapy.
After platinum:
- in pMMR (no repair deficiency) the combination of pembrolizumab with lenvatinib is used;
- in dMMR/MSI-H immunotherapy alone is possible (pembrolizumab, dostarlimab);
- hormonal therapy (progestins, letrozole and others) suits slowly growing hormone-driven low-grade disease;
- in HER2-positive serous cancer trastuzumab with chemotherapy is considered (HER2);
- clinical trials (about clinical trials).
At progression it is important to confirm it on scans and discuss the next line: progression on treatment.
Can fertility be preserved
In a very narrow group of young women with early well-differentiated cancer limited to the lining, fertility-sparing hormonal treatment (progestins or a levonorgestrel intrauterine system) with frequent checks (hysteroscopy, biopsy) is discussed. After childbearing plans are complete, removal of the uterus is usually advised. The decision is made with a gynaecological oncologist and a reproductive specialist. More on what can be done before treatment: fertility preservation before chemotherapy.
Side effects
On carboplatin and paclitaxel the most common are:
- low white cells and risk of infection (fever on chemotherapy);
- anaemia (anaemia in cancer);
- neuropathy (numbness and tingling in the fingers, more: neuropathy in chemotherapy);
- hair loss (hair loss);
- nausea, fatigue, muscle and joint pain.
On immunotherapy, inflammation of the bowel, thyroid, skin and other organs is possible (immunotherapy side effects). On lenvatinib raised blood pressure, diarrhoea, protein in urine and fatigue are common.
After removal of the ovaries, women before menopause enter surgical menopause, so symptoms (hot flushes, dryness, bone health) and support options should be discussed; the decision about hormone replacement is made individually with the doctor.
Follow-up after treatment
Check-ups are more frequent in the first years (usually every 3–6 months) and then less often. They include examination, gynaecological assessment and imaging when indicated. Tell your doctor about new discharge, pain, leg swelling, shortness of breath and weight loss. Recurrence is more likely in the first 2–3 years but can occur later (recurrence after years).
What to ask your doctor
- What are my histological type, grade and stage?
- Was molecular testing done (MMR, p53, POLE)? Which subtype is the tumour?
- Which risk group am I in and what does it mean for treatment?
- Is anything needed after surgery: brachytherapy, radiotherapy or chemotherapy?
- If chemotherapy is needed, which regimen, how many cycles and which side effects to expect?
- Will immunotherapy be an option if the disease returns?
- Is a genetic consultation needed (if dMMR)?
When to seek urgent help
- temperature of 38 °C or above, chills on chemotherapy;
- heavy vaginal bleeding;
- severe abdominal or pelvic pain, inability to pass urine;
- shortness of breath, chest pain, swelling and pain in one leg (possible thrombosis, see thrombosis in cancer);
- severe diarrhoea or vomiting when you cannot drink.
Can I get a second opinion
Yes, especially if you were offered a regimen without discussion of the molecular subtype, chemotherapy was given or not given for unclear reasons, or you are unsure about the stage. Prepare in advance the pathology, operation report, molecular test results and scans: documents for a second opinion, preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information: gynaecological tumours.
Sources
- Endometrial Cancer Treatment (PDQ) — National Cancer Institute
- ESMO Clinical Practice Guidelines — ESMO
- Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
- Clinical guidelines (Russia) — Russian Ministry of Health
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
